PDIA3 and central nervous system cancer: The research by Zou et al. [20] suggested that patients with glioma with high PDIA3 expression had poor survival prognosis, and PDIA3 could be used as an independent prognostic biomarker of diffuse glioma, whose down-regulation might contribute to the survival of patients undergoing chemotherapy and radiotherapy.